The broad pre-clinical and clinical trial programme, involving over 1,300 patients, has examined how we can deliver meaningful clinical benefits to patients with early Alzheimer’s disease. We continue to invest in studies that improve our understanding of the field so that we can offer patients with Alzheimer’s disease the best possible nutritional support during the early stages of their illness. See below an overview of our clinical trial programme in which a unique combination of nutrients has been tested or is tested in four randomised clinical trials, including the Souvenir I and II studies and the LipiDiDiet study and two smaller imaging studies.
